Narix Pharmaceuticals Private Limited

Vocabria (Cabotegravir) Oral Tablet Next-Generation INSTI for HIV Treatment & PrEP Narix Pharmaceuticals Narix Pharmaceuticals supplies Cabotegravir Oral Tablets, a next-generation integrase strand transfer inhibitor used as oral lead-in before long-acting injectable cabotegravir + rilpivirine ART, and as HIV pre-exposure prophylaxis (PrEP). Key Therapeutic Uses: � HIV-1 ART � oral lead-in (4 weeks) before LA-injectable regimen � HIV PrEP � long-acting injectable cabotegravir (LAI-PrEP) � HIV suppressed patients transitioning to 2-monthly injectable � Alternative to daily oral PrEP (TDF/FTC) Available Strengths: 30 mg Product Highlights: � Enables transition to every-2-month injectable ART � Superior PrEP efficacy vs daily oral TDF/FTC (HPTN 083/084) � WHO-GMP, DCGI approved � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #CabotegravirTablet #VocabriaGeneric #NextGenINSTI #HIVPrEP #LongActingART #CabotegravirManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine